Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions (INSPIRE)
Feasibility of a Remote Collaborative Care-Facilitated Contingency Management-Exercise Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions
The purpose of this study is to evaluate the feasibility and preliminary effectiveness of increasing control over stimulant use and physical health through incentivized rehabilitation (INSPIRE). INSPIRE is a 12-week remotely-delivered collaborative care intervention for rural patients with Methamphetamine-Associated Heart Failure (Me-HF) or Methamphetamine-Associated Pulmonary Arterial Hypertension (Me-PAH) featuring smartphone-based contingency management incentivizing participation in remote synchronous rehabilitation.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Michael A Incze, MD
- Telefonnummer: 801-581-2000
- E-mail: Michael.Incze@hsc.utah.edu
Studiesteder
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84108
- Rekruttering
- University of Utah Health
-
Kontakt:
- Michael A Incze, MD
- Telefonnummer: 801-581-2000
- E-mail: Michael.Incze@hsc.utah.edu
-
Kontakt:
- Dominique Ingram
- Telefonnummer: 801-581-2000
- E-mail: dominique.ingram@utah.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Active methamphetamine use determined by positive urine drug testing within the past 3 months and/or self-reported current use
- Current diagnosis of chronic heart failure or pulmonary hypertension documented in the electronic health record
- Possession of a smartphone
- Able to participate in virtual exercise rehabilitation
Exclusion Criteria:
- Currently incarcerated
- Unable to interact with smartphone app and/or virtual health coaching sessions in English
- Unstable arrhythmia, defined as any known arrhythmia that is associated with hemodynamic effects like syncope, hypotension, or decompensated heart failure
- Decompensated chronic heart failure or pulmonary hypertension
- NYHA class IV symptoms
- Myocardial infarction within the past 3 months, percutaneous coronary intervention within the past 2 weeks, coronary artery bypass graft within the past 3 months, or implantable cardiac defibrillator/cardiac resynchronization therapy/pacemaker implantation within the last 6 weeks
- Unstable angina, uncontrolled hypertension, acute myocarditis/pericarditis, intracardiac thrombus
- Severe symptomatic aortic stenosis
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: INSPIRE
Participants randomized to INSPIRE will receive usual medical care plus a 12-week program featuring collaborative care and app-based contingency management incentivizing participation in remotely-delivered synchronous exercise rehabilitation sessions |
Standard medical care plus a 12-week program featuring collaborative care and app-based contingency management incentivizing participation in remotely-delivered synchronous exercise rehabilitation sessions |
|
Aktiv komparator: Usual Care
Participants randomized to Usual Care will receive standard of care services routinely available at the University of Utah, including specialty cardiology, pulmonology and addiction care and in-person cardiac and pulmonary rehabilitation services |
Standard care services routinely available at the University of Utah Health, including specialty cardiology, pulmonology and addiction care and in-person cardiac and pulmonary rehabilitation services |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in metabolic equivalents (METs)
Tidsramme: Baseline, 1, 3, and 6 months
|
Change in METs before and after the intervention measured via Duke Activity Status Indicator (DASI) |
Baseline, 1, 3, and 6 months
|
|
Change in self-reported substance use
Tidsramme: Baseline, 1, 3, and 6 months
|
Change in self-reported substance use amount and frequency via Timeline Follow Back (TLFB) |
Baseline, 1, 3, and 6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of Life - Short Form 20
Tidsramme: Baseline, 1, 3, and 6 months
|
Measure of participants' quality of life using the Short Form 20 (SF-20) questionnaire. The score range of this survey is 0-100, with higher scores indicating better overall quality of life. |
Baseline, 1, 3, and 6 months
|
|
Quality of Life - Kansas City Cardiomyopathy Questionnaire-12
Tidsramme: Baseline, 1, 3, and 6 months
|
Measure of participant's quality of life using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). The score range of this survey is 0-100, with higher scores indicating better functioning and less limitation from heart failure symptoms. |
Baseline, 1, 3, and 6 months
|
|
Self-Efficacy Related to Avoiding Substance Use with the Drug Avoidance Self-Efficacy Scale (DASES). The score range of this survey is 0-96, with higher scores indicating better self-efficacy to avoid substance use.
Tidsramme: Baseline, 1, 3, and 6 months
|
Measure of self-efficacy to avoid substance use with the Drug Avoidance Self-Efficacy Scale (DASES). |
Baseline, 1, 3, and 6 months
|
|
Recovery Capital using the Brief Assessment of Recovery Capital (BARC-10) questionnaire
Tidsramme: Baseline, 1, 3, and 6 months
|
Measure of the internal and external resources (recovery capital) that help initiate and sustain recovery from substance use disorder, using the Brief Assessment of Recovery Capital (BARC-10) questionnaire. The score range of this survey is 10-60, with higher scores indicating a greater amount of recovery capital. |
Baseline, 1, 3, and 6 months
|
|
Contingency Management App Engagement
Tidsramme: 3 months and 6 months
|
Number of weekly App Log-Ins, Contingency Management Draws and Earnings |
3 months and 6 months
|
|
Hospital Readmissions in the Past 30 Days
Tidsramme: Baseline, 1, 3, and 6 months
|
Self-Reported Hospital admissions in the past 30 days using Timeline Follow Back |
Baseline, 1, 3, and 6 months
|
|
Emergency Department Visits in the Past 30 days
Tidsramme: Baseline, 1, 3, and 6 months
|
Self-Reported number of ED visits in the past 30 days using Timeline Follow Back |
Baseline, 1, 3, and 6 months
|
|
Urgent Care Visits in the Past 30 Days
Tidsramme: Baseline, 1, 3, and 6 months
|
Self-Reported number of urgent care visits in the past 30 days using Timeline Follow Back |
Baseline, 1, 3, and 6 months
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
INSPIRE Acceptability assessed via 4-item Intervention Acceptability Measure (IAM)
Tidsramme: immediately after the intervention (12 weeks from randomization)
|
Measure of INSPIRE acceptability through the IAM survey collected one time from all patient participants one time at the end of the intervention |
immediately after the intervention (12 weeks from randomization)
|
|
INSPIRE Appropriateness assessed via 4-item Appropriateness of Intervention Measure (AIM)
Tidsramme: immediately after the intervention (12 weeks from randomization)
|
Measure of INSPIRE appropriateness through Appropriateness of Intervention Measure (AIM) collected one time from all patient participants one time at the end of the intervention |
immediately after the intervention (12 weeks from randomization)
|
|
Reach of the Intervention Over the Entire Study Period
Tidsramme: Measured starting from the first randomization and ending after the final participant is randomized (up to 100 weeks after first randomization)
|
Number of different counties and states represented by enrolled participants measured from the first randomization to the final randomization. |
Measured starting from the first randomization and ending after the final participant is randomized (up to 100 weeks after first randomization)
|
|
Sustainment of intervention
Tidsramme: Measured between 12 weeks (end of intervention) and 24 weeks after randomization
|
Number of intervention participants who continue to log into the contingency management/peer support app in the three months after the intervention ends as assessed through app utilization data |
Measured between 12 weeks (end of intervention) and 24 weeks after randomization
|
|
Feasibility
Tidsramme: Measured starting from the first randomization and ending after the final participant has completed the intervention, discontinued the study, or was lost to follow-up (up to 112 weeks after first randomization)
|
Average number of enrollments per month and percentage of enrolled participants who complete the intervention |
Measured starting from the first randomization and ending after the final participant has completed the intervention, discontinued the study, or was lost to follow-up (up to 112 weeks after first randomization)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Michael A Incze, MD, University of Utah
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB_00204022
- 1R21DA066520-01 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual de-identified responses to the following surveys will be preserved and shared: 1) SF-20, 2) Kansas City Cardiomyopathy Questionnaire-12, 3) DASI, 4) TLFB data, 5) Drug Avoidance Self-Efficacy Scale, 6) BARC-10, 7) Appropriateness of Intervention Measure, 8) Intervention Acceptability Measure, and 9) App engagement and CM earnings data, 10) Self-reported data on substance use and acute care utilization, 11) demographic and substance use history enrollment surveys. De-identified biometric data and qualitative interview transcripts will also be preserved and shared.
All data will be stored within a secure computing environment. All participant identifiers (e.g., names and addresses) will be removed and maintained in a secure file for future contact purposes. Participant identifiers will not be shared.
IPD-delingstidsramme
Data will be available within 12 months of study conclusion
IPD-delingsadgangskriterier
Data will be archived in The Hive. The Hive is a publicly-accessible repository for research data generated by UHealth researchers, students, and staff. It is maintained by the Marriott Library IT and Digital Collections. The Hive has policies and procedures in place that will provide data access to qualified researchers, fully consistent with NIH data-sharing policies and applicable laws and regulations. Deidentified data within The Hive will be shared with other investigators who propose specific aims/hypotheses in order to identify the data elements required and who receive agreement from the appropriate project leaders.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .